Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer

Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of oestrogen receptor (ER)α. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERα-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of ERα-positive tumours. Notably, Aurora-A inhibitor MLN8237, which is currently in clinical trial, synergizes with tamoxifen and overcomes tamoxifen resistance. Furthermore, Aurora-A interacts with and phosphorylates ERα on serine-167 and -305, leading to increase in ERα DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ERα-positive but not ERα-negative breast cancers. These data suggest that Aurora-A has a pivotal role in tamoxifen resistance and ERα is a bona fide substrate of Aurora-A. Thus, Aurora-A represents a prognostic marker in ERα-positive tumour and a critical therapeutic target in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independent or concurrent agent in tamoxifen-resistant tumour.

• Publication year

  2013

• Venue

  Oncogene

• Publication date

  2013-10-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2013.444PMID 24166501PMCID 4002670
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cells

  2014cited by this paper
• Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

  2012cited by this paper
• Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

  2012cited by this paper
• The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells

  2012cited by this paper
• The role of S6K1 in ER-positive breast cancer

  2012cited by this paper
• Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells

  2012cited by this paper
• Cracking the estrogen receptor's posttranslational code in breast tumors.

  2011influential reference
• Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

  2011cited by this paper
• Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

  2011cited by this paper
• Clinical significance of estrogen receptor phosphorylation.

  2011cited by this paper
• Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer

  2010cited by this paper
• TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression.

  2010cited by this paper
• IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer.

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

  2010cited by this paper
• An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

  2010cited by this paper
• PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer

  2010cited by this paper
• Biological determinants of endocrine resistance in breast cancer

  2009cited by this paper
• IKKϵ Phosphorylation of Estrogen Receptor α Ser-167 and Contribution to Tamoxifen Resistance in Breast Cancer*

  2009cited by this paper
• Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

  2009cited by this paper
• Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA

  2009cited by this paper
• Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

  2007cited by this paper
• HEF1-dependent Aurora A activation induces disassembly of the primary cilium.

  2007cited by this paper
• Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

  2007cited by this paper
• Aurora-A amplification associated with BRCA2 mutation in breast tumours.

  2007cited by this paper
• Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation

  2006cited by this paper
• Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation.

  2006cited by this paper
• Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.

  2006cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Aurora-A site specificity: a study with synthetic peptide substrates.

  2005cited by this paper
• Aurora-A Kinase Regulates Telomerase Activity through c-Myc in Human Ovarian and Breast Epithelial Cells

  2004cited by this paper
• Molecular Mechanisms, Physiological Consequences and Pharmacological Implications of Estrogen Receptor Action

  2004cited by this paper
• Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.

  2004cited by this paper
• Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215*

  2004cited by this paper
• Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Targeting Aurora-2 kinase in cancer.

  2003cited by this paper
• Surgeons as an Integral Part of the Cancer Research Team

  2003cited by this paper
• AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

  2003cited by this paper
• Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

  2003cited by this paper
• P21‐activated kinase‐1 phosphorylates and transactivates estrogen receptor‐α and promotes hyperplasia in mammary epithelium

  2002cited by this paper
• Estrogen receptor interaction with estrogen response elements.

  2001cited by this paper
• Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

  2001cited by this paper
• Estrogen receptor: current understanding of its activation and modulation.

  2001cited by this paper
• Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

  2001cited by this paper
• Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

  1999cited by this paper
• pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167

  1998cited by this paper
• Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

  1995cited by this paper
• Possible mechanisms in the emergence of tamoxifen-resistant breast cancer.

  1995cited by this paper
• Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

  1994cited by this paper

• Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets

  2025cites this paper
• Seize the engine: Emerging cell cycle targets in breast cancer

  2024cites this paper
• PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer

  2024cites this paper
• Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor α

  2023cites this paper
• Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis

  2023cites this paper
• Emerging roles of Aurora-A kinase in cancer therapy resistance

  2023cites this paper
• Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity

  2023cites this paper
• TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth

  2023cites this paper
• Recent Updates on Oncogenic Signaling of Aurora Kinases in Chemosensitive, Chemoresistant Cancers: Novel Medicinal Chemistry Approaches for Targeting Aurora Kinases.

  2023cites this paper
• Immunoprecipitation Analyses of Estrogen Receptor α Phosphorylated at Serine 216 in the Mouse Liver.

  2022cites this paper
• p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes.

  2021cites this paper
• Nuclear Aurora kinase A triggers programmed death‐ligand 1‐mediated immune suppression by activating MYC transcription in triple‐negative breast cancer

  2021cites this paper
• OTUD6A Is an Aurora Kinase A-Specific Deubiquitinase

  2021cites this paper
• Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

  2021cites this paper
• Mps1 contributes to tamoxifen resistance in Breast Cancer through phosphorylation of ERα

  2021cites this paper
• РОЛЬ ЦИКЛИНА D1 В МЕХАНИЗМАХ РЕЗИСТЕНТНОСТИ К ГОРМОНАЛЬНОЙ ТЕРАПИИ ТАМОКСИФЕНОМ

  2020cites this paper
• roLe of CYCLin d1 in the meChanisms of tamoxifen resistanCe

  2020cites this paper
• ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE

  2020cites this paper
• A data driven approach to identify ZM-447439 as a potential repurposed drug to overcome tamoxifen-resistance in breast cancer

  2020cites this paper
• San Huang Decoction Targets Aurora Kinase A to Inhibit Tumor Angiogenesis in Breast Cancer

  2020cites this paper
• Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability

  2020cites this paper
• Discovery of inhibitors of Aurora/PLK targets as anti-cancer agents.

  2019cites this paper
• Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer

  2019cites this paper
• Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer

  2019cites this paper
• Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer

  2019cites this paper
• Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists

  2018influential citation
• Aurora A kinase activity is required to maintain an active spindle assembly checkpoint during prometaphase

  2018cites this paper
• Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer

  2018cites this paper
• Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration

  2018cites this paper
• LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

  2018cites this paper
• Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer

  2016cites this paper
• Syddansk Universitet HIF 2 contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells

  2016cites this paper
• An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

  2016cites this paper
• Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

  2016cites this paper
• HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells

  2016cites this paper
• Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

  2015cites this paper
• Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells

  2015cites this paper
• Aurora A and Mcl-1: new potential treatment targets in antiestrogen-resistant breast cancer

  2015influential citation
• The Effect of IKKbeta on Estrogen Receptor Positive Breast Cancer Phenotypes

  2015cites this paper
• Syddansk Universitet Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

  2015cites this paper
• New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

  2015cites this paper
• Aurora Kinase Inhibitors in Breast Cancer Treatment

  2015cites this paper
• Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells

  2015cites this paper
• A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

  2014cites this paper
• Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers

  2014cites this paper